Comparing imaging quality of two types of CT scans
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
This study is testing if a new type of CT scan can produce better images than a standard CT scan for people with different medical conditions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 339 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Bron, Avenue Doyen Lépine) |
| Trial ID | NCT04328181 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the imaging quality and diagnostic confidence of Spectral Photon Counting Computed Tomography (SPCCT) compared to Dual Energy Computed Tomography (DECT). The study will involve various scanning protocols across multiple anatomical regions, including diabetic foot, coronary arteries, and lung parenchyma, to assess improvements in image quality with and without contrast agents. By analyzing different medical conditions, the study seeks to provide a comprehensive understanding of the advantages of SPCCT over DECT.
Who should consider this trial
Good fit: Ideal candidates include patients with conditions such as diabetic foot ulcers, coronary artery disease, or urinary stones.
Not a fit: Patients without the specified medical conditions or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to enhanced imaging techniques that improve diagnostic accuracy for various medical conditions.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving imaging techniques, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients presenting following one of following medical conditions: 1. Asymptomatic type 1 or 2 diabetes as regard to cardiovascular risks 2. Diabetic foot ulcer 3. Adrenal glands lesions: Adrenal incidentaloma or hyperaldosteronism or macroadenoma 4. Urinary stone(s) 5. Known Coronary artery disease: Stent imaging or control of calcified plaques 6. Diffuse Interstitial Lung Diseases: Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Ground Glass Opacification, Chronic Thromboembolic Pulmonary Hypertension 7. Conductive hearing loss 8. Brain stroke (late or post thrombectomy) 9. Intracranial arteriovenous malformation treated with coils or Onyx 10. Joints diseases in haemophilia 11. Ear/temporal bone 12. Colorectal carcinosis 13. Dissection aortique de type A opérée ou de type B non opérée, hématome intramural * Patient has accepted to participate to the study and has signed the written consent; * Pre-menopausal women only: Negative urinary pregnancy test on the day of imaging before the administration of study drug; * Patient is affiliated to the French social security Exclusion Criteria: * Contraindication to the use of iodine containing contrast media (including subjects with suspicion for/or known to have NSF) (if injection); * History of severe allergic or anaphylactic reaction to any allergen including drugs and contrast agents (as judged by the investigator, taking into account the intensity of the event); * History of delayed major or delayed cutaneous reaction to Iomeron injection * Estimated Glomerular Filtration Rate (eGFR) value \< 30 mL/min/1.73 m2 derived from a serum creatinine result within 1 month before the imaging for examinations with contrast agent. * Any subject on hemodialysis or peritoneal dialysis; * Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery); * Pregnant or nursing (including pumping for storage and feeding); * Patient under guardianship, curatorship or safeguard of justice.
Where this trial is running
Bron, Avenue Doyen Lépine
- Hôpital Cardiologique Louis Pradel - Hospices Civils de Lyon — Bron, Avenue Doyen Lépine, France (Recruiting)
Study contacts
- Principal investigator: Philippe DOUEK, Pr — Service de Radiologie, l'Hôpital Louis Pradel - Hospices Civils de Lyon
- Study coordinator: Philippe DOUEK, Pr
- Email: douek@creatis.insa-lyon.fr
- Phone: 04 72 07 18 83
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.